Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Interest & Investment Income (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Interest & Investment Income for 15 consecutive years, with $25.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income rose 14.67% year-over-year to $25.8 million, compared with a TTM value of $90.3 million through Dec 2025, down 0.77%, and an annual FY2025 reading of $90.3 million, down 0.77% over the prior year.
  • Interest & Investment Income was $25.8 million for Q4 2025 at Neurocrine Biosciences, up from $22.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $25.8 million in Q4 2025 and bottomed at $800000.0 in Q3 2021.
  • Average Interest & Investment Income over 4 years is $15.8 million, with a median of $20.6 million recorded in 2025.
  • The sharpest move saw Interest & Investment Income tumbled 75.0% in 2021, then skyrocketed 127.55% in 2024.
  • Year by year, Interest & Investment Income stood at $800000.0 in 2021, then surged by 2125.0% to $17.8 million in 2023, then grew by 26.4% to $22.5 million in 2024, then grew by 14.67% to $25.8 million in 2025.
  • Business Quant data shows Interest & Investment Income for NBIX at $25.8 million in Q4 2025, $22.2 million in Q3 2025, and $20.6 million in Q2 2025.